跳到主要內容

Severino Michael 的 Form 4 申報

AbbVie Inc.(ABBV),2022/5/10 申報

申報編號
0001179110-22-002947
申報時間
2022/5/10
交易日
2022/5/6-5/10
申報延遲
4 天
10b5-1 計畫
表單沒有這欄(2023 年以前)

這份申報列了 15 筆非衍生性交易、6 筆衍生性交易。公開市場賣出合計 $4,534 萬。交易後 4 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Severino MichaelCIK 0001609447高階主管(副董事長)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2022/5/6Common Stock, $0.01 par valueM行使選擇權取得+74,309$54.44+$4,045,381.96226,412直接
2022/5/6Common Stock, $0.01 par valueM行使選擇權取得+25,691$54.86+$1,409,408.26252,103直接
2022/5/6Common Stock, $0.01 par valueS賣出處分−40,176$150.10F1−$6,030,417.6211,927直接
2022/5/6Common Stock, $0.01 par valueS賣出處分−45,988$151.13F2−$6,950,166.44165,939直接
2022/5/6Common Stock, $0.01 par valueS賣出處分−13,836$151.78F3−$2,100,028.08152,103直接
2022/5/9Common Stock, $0.01 par valueM行使選擇權取得+66,299$54.86+$3,637,163.14218,402直接
2022/5/9Common Stock, $0.01 par valueM行使選擇權取得+33,701$58.88+$1,984,314.88252,103直接
2022/5/9Common Stock, $0.01 par valueS賣出處分−47,215$149.53F4−$7,060,058.95204,888直接
2022/5/9Common Stock, $0.01 par valueS賣出處分−31,714$150.63F5−$4,777,079.82173,174直接
2022/5/9Common Stock, $0.01 par valueS賣出處分−21,071$151.42F6−$3,190,570.82152,103直接
2022/5/10Common Stock, $0.01 par valueM行使選擇權取得+70,779$58.88+$4,167,467.52222,882直接
2022/5/10Common Stock, $0.01 par valueM行使選擇權取得+29,221$61.36+$1,793,000.56252,103直接
2022/5/10Common Stock, $0.01 par valueS賣出處分−22,873$151.16F7−$3,457,482.68229,230直接
2022/5/10Common Stock, $0.01 par valueS賣出處分−28,536$152.24F8−$4,344,320.64200,694直接
2022/5/10Common Stock, $0.01 par valueS賣出處分−48,591$152.83F9−$7,426,162.53152,103直接

衍生性證券(表 II)

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數;單價與金額是衍生證券本身的價格,交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日證券交易標的股數單價金額交易後持有持有方式旗標
2022/5/6Common StockM行使選擇權處分−74,309$54.44−$4,045,381.960直接
2022/5/6Common StockM行使選擇權處分−25,691$54.86−$1,409,408.2666,299直接
2022/5/9Common StockM行使選擇權處分−66,299$54.86−$3,637,163.140直接
2022/5/9Common StockM行使選擇權處分−33,701$58.88−$1,984,314.8870,779直接
2022/5/10Common StockM行使選擇權處分−70,779$58.88−$4,167,467.520直接
2022/5/10Common StockM行使選擇權處分−29,221$61.36−$1,793,000.5670,879直接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.58 to $150.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F2

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.58 to $151.57 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F3

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.58 to $151.95 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F4

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.04 to $150.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F5

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.04 to $151.03 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F6

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.04 to $151.93 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F7

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.55 to $151.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F8

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.55 to $152.54 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

F9

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.55 to $153.50 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

表 I 有 1 筆交易的價格引用這則附註。

備註

The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

看 SEC EDGAR 上的完整原文 (在新分頁開啟)